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Design of allele-specific inhibitors to probe protein
kinase signaling
Anthony C. Bishop*, Kavita Shah*, Yi Liu*, Laurie Witucki*, Chi-yun Kung* 
and Kevan M. Shokat*†
Background: Deconvoluting protein kinase signaling pathways using
conventional genetic and biochemical approaches has been difficult because of
the overwhelming number of closely related kinases. If cell-permeable inhibitors
of individual kinases could be designed, the role of each kinase could be
systematically assessed.
Results: We have devised an approach combining chemistry and genetics to
develop the first highly specific cell-permeable inhibitor of the oncogenic
tyrosine kinase v-Src. A functionally silent active-site mutation was made in v-
Src to distinguish it from all other cellular kinases. A tight-binding cell-
permeable inhibitor of this mutant kinase that does not inhibit wild-type kinases
was designed and synthesized. In vitro and whole-cell assays established the
unique specificity of the mutant v-Src–inhibitor pair. The inhibitor reversed cell
transformation by the engineered but not the ‘wild type’ v-Src, establishing that
changes in cellular signaling can be attributed to specific inhibition of the
engineered kinase. The generality of the method was tested by engineering
another tyrosine kinase, Fyn, to contain the corresponding active-site mutation
to the one in v-Src. The same compound that inhibited mutant v-Src could also
potently inhibit the engineered Fyn kinase.
Conclusions: Allele-specific cell-permeable inhibitors of individual Src family
kinases can be rapidly developed in an approach that should be applicable to
all kinases. This approach will be useful for the deconvolution of kinase-
mediated cellular pathways and for validating novel kinases as good targets for
drug discovery both in vitro and in vivo.
Background
Protein phosphorylation is a central mediator of many
different cell-signaling events. The dissection of kinase
signaling pathways is a challenge to existing biochemical
and genetic methods for several reasons. The pathways
are highly interconnected, and biochemical studies of
individual kinases have revealed remarkable functional
similarities between kinases [1]. Also, many kinase gene
knockouts have shown surprisingly mild phenotypes,
either because kinases recognize substrates redundantly or
because of compensation by other kinases during develop-
ment [2–4]. Cell-permeable inhibitors that are highly
specific for one protein kinase would provide several key
advantages over the gene ‘knockout’ approach to enzyme
inactivation. Inhibitor treatment allows the cell no time to
compensate adaptively for the missing activity of the
target kinase. In addition, small molecules can be adminis-
tered to a cell in varying concentrations, allowing observa-
tion of the effects of partial as well as total inhibition of
the target kinase. Finally, inhibition of kinase activity at
the catalytic active site in the Src-homology 1 (SH1)
domain would presumably not disrupt important cellular
localization and protein–protein binding interactions that
are generally mediated through other domains [1].
Despite their value in signal-transduction research, highly
selective kinase inhibitors have proven very difficult to
obtain. This is presumably because of the enormous size
of the kinase superfamily and the highly conserved nature
of kinase active sites, which make the design of an
inhibitor that targets a given kinase an enormously chal-
lenging combinatorial problem [1,5–7]. The development
of kinase-specific inhibitors has been a major focus of anti-
tumor drug discovery research because of the ubiquitous
connection between oncogenic transformation and consti-
tutively active protein kinases [8–10]. Recently, signifi-
cant progress has been made in the synthesis and
identification of molecules that can discriminate between
different receptor tyrosine kinases. Molecules that are
highly selective for epidermal growth factor receptor
(EGF-R) [11,12], platelet-derived growth factor receptor
(PDGF-R) [13] and fibroblast growth factor receptor
(FGF-R) [14,15] tyrosine kinases have been identified.
Importantly, crystal structures of inhibitors bound to
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kinases [15] and modeling studies [12,16] are facilitating
the structure-based design of highly selective molecules.
Despite these efforts, few inhibitors that are entirely spe-
cific for a single cytoplasmic protein kinase have been
identified [17], and no general methods for specifically tar-
geting a given kinase have been described. 
We have devised a combined chemical and genetic strat-
egy that allows for the generation of ‘chemical-sensitive’
mutant kinases each of which is uniquely inhibited by a
rationally designed small-molecule inhibitor. Our
approach involves engineering into the active site of the
kinase of interest a unique ‘pocket’ resulting from the
introduction of a functionally silent mutation. A specific
inhibitor of the engineered kinase is then synthesized by
derivatizing a known kinase inhibitor with a bulky chemi-
cal group designed to fit the novel active-site pocket. The
bulky group prevents the compound from inhibiting wild-
type kinases, which do not have the pocket. Successful
complementary design therefore results in interactions
between only the engineered kinase and the inhibitor.
Transfection of cells with the gene encoding the engi-
neered kinase generates cells in which only this one
kinase can be blocked by the designed inhibitor
(Figure 1). Importantly, because the mutant kinase has
the same biological function as the wild-type kinase, an
inhibitor of the mutant will affect cell signaling in the
same manner as would a selective inhibitor of the endoge-
nous kinase. The ability to observe the phenotype of cells
after selective inhibition of a protein kinase provides a
rapid method for determining the unique roles of individ-
ual kinases in signal-transduction cascades.
We have targeted the Src family of protein tyrosine kinases
for specific inhibitor design because of their ubiquitous
functional importance in cells [3,18]. Despite intense inves-
tigation, the roles of individual Src family members have
been difficult to assess because many of them co-localize in
cells and many have similar sequences. Although some
potent inhibitors of Src family kinases are known [19,20],
no molecules have been identified that can effectively dis-
criminate (≥ 20-fold selectivity for one Src family member)
between these closely related enzymes [10].
Two Src kinases, v-Src and Fyn, were chosen as the
primary targets of our mutant kinase–inhibitor pair design.
Src kinase has emerged as a leading drug target because of
its implication in the oncogenesis of breast, lung and colon
cancers [10]. Although v-Src is the prototype for oncogenic
tyrosine kinases, no small-molecule inhibitors that are
highly selective for this kinase have been discovered [10].
Fyn is a Src family tyrosine kinase that is important in
lymphocyte activation mediated by the T-cell receptor
[3,21]. Src and Fyn share a similar domain structure and
have approximately 85% amino-acid identity in their
catalytic domains [22]. The close structural relationship of
the Src family members provides the ideal test of our
ability to engineer enzyme–inhibitor specificity that can
distinguish between highly homologous kinases. If one
can discriminate between these closely related Src family
members using a cell-permeable inhibitor, it is likely that
specificity for members of other protein-kinase families
can also be achieved using a similar approach.
Results and discussion
Enzyme engineering
From our previous efforts to engineer kinases with novel
ATP specificity [23,24], we identified a functionally con-
served residue (Ile 338) in the ATP-binding pocket of v-
Src that could be mutated to glycine without altering the
phosphoacceptor specificity or biological function of the
kinase. The mutation (I338G) causes only a modest drop
in the kcat of v-Src, a modest increase in the Km for ATP
[24] and no quantitative change in the level of fibroblast
transformation compared to the non-engineered (‘wild-
type’) protein (K.S., unpublished observations). Crystal
structures of ATP-bound protein kinases have in all cases
revealed close contact and interaction between the residue
corresponding to 338 in Src and ATP [25–28]. Analysis of
protein kinase sequence alignments confirms that residue
338 contains a bulky side chain (usually threonine,
isoleucine, leucine, methionine or phenylalanine) in all
known eukaryotic protein kinases [29]. Thus, the muta-
tion to glycine at residue 338 should create a novel pocket
that is not present in any wild-type kinase. Because of the
expanded ATP-binding site, the glycine mutant kinases
should bind bulky inhibitors that could not bind wild-type
kinases. Using standard methods, we cloned, expressed
and purified the glutathione-S-transferase (GST) fusion
protein of the wild-type and I338G v-Src catalytic domains
as described [23,24]. Wild-type Fyn, T339G Fyn and the
wild-type Abl tyrosine kinase were also expressed and
purified as GST fusion proteins.
Inhibitor design and synthesis
To test our basic design strategy, we screened the wild-
type and I338G v-Src SH1 domains against a previously
synthesized panel of N-6-substituted adenosine molecules
[23] for selective inhibition of I338G v-Src over wild-type
v-Src. Because adenosine is only a moderate inhibitor of
Src family tyrosine kinases, we did not expect to discover
a potent inhibitor of the engineered kinase. As expected,
all of the N-6 adenosine analogues inhibited I338G v-Src
more potently than wild-type v-Src (data not shown). The
most potent inhibitor found in this screen was N-6
cyclopentyloxyadenosine (1, Figure 2a) with a 50%
inhibitory concentration (IC50) of 1 µM for I338G v-Src.
Subsequent experiments to test for selectivity demon-
strated that N-6 cyclopentyloxyadenosine showed no
detectable in vitro inhibition of wild-type v-Src or Fyn at
concentrations up to 400 µM. This first screen encouraged
us to pursue the strategy of developing novel inhibitors of
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I338G v-Src because our design had allowed us readily to
overcome the selectivity barriers that are major problems
in conventional inhibitor design.
As inhibitors, adenosine analogues are not ideal because
adenosine performs many cellular functions and binds a
large number of cellular proteins. N-6 adenosine analogues
have been shown to act as adenosine-receptor agonists and
antagonists [30], and N-6 adenosine analogues might con-
ceivably act as substrates for nucleoside kinases. For these
reasons, we turned to a class of known tyrosine-kinase
inhibitors that are not direct analogues of biologically
known molecules. Our design strategy called for a core
structure that exhibits potent inhibition of multiple wild-
type kinases and is easily synthesized. Also, the binding
orientation of the molecule in the enzyme active site must
be known or readily predictable. In addition, the molecule
must bind in a manner in which the site pointing toward
Ile338 can be easily modified. As our core inhibitor struc-
ture we chose 4-amino-1-tert-butyl-3-phenylpyrazolo[3,4-
d]pyrimidine (2, Figure 2b). This molecule is a derivative
of 4-amino-1-tert-butyl-3-(p-methylphenyl)pyrazolo[3,4-d]
pyrimidine (PP1) that was reported to be a potent Src
family kinase inhibitor by Hanke and co-workers [19]. On
the basis of the co-crystal structure of the Src family kinase
Hck bound to the general kinase inhibitor quercetin 
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The specificity problems associated with using small-molecule protein-
kinase inhibitors to deconvolute cell signaling. Kinase catalytic domains
(red ovals) are highly conserved. Thus, (a) the majority of potent
inhibitors block the activity of closely related kinases and broadly
down-regulate pathways mediated by kinase activity. (b) The selective
protein kinase inhibition approach described here. A space-creating
mutation is introduced into the ATP-binding site of the kinase of choice
(Src). This mutation creates an active-site pocket in Src that can be
uniquely recognized by the rationally designed small-molecule inhibitor.
The inhibitor contains a bulky chemical group that makes it unable to
bind wild-type protein kinases. Design of the complementary
kinase–inhibitor pair allows for highly selective inhibition of the target
kinase in the context of a whole cell. S indicates serine and Y indicates
tyrosine.
(5, Figure 3) [25,31], we postulated that 2 binds to Src
family kinases in a conformation similar to that of ATP.
The predicted binding orientation of 2 in Hck is shown in
an overlay with the known Hck co-crystal structures of
AMPPNP (6) and quercetin (Figure 3b) [25]. In this con-
formation, the easily derivatizable N-4 position of 2 corre-
sponds to the N-6 of ATP (close contact with residue 338,
Figure 3c) and the tert-butyl moiety roughly corresponds to
the ribose ring of ATP. We further hypothesized that, in
this orientation, the C-3 phenyl ring of 2 could bind in a
pocket that surrounds the N-7 of ATP as seen in the
Hck–quercetin co-crystal structure [25]. This analysis led
us to synthesize a small panel of N-4 derivatized analogues
of 2 [32,33] (Figure 2).
Identification of a uniquely selective inhibitor
The panel of pyrazolo[3,4-d]pyrimidines was screened
against wild-type and I338G v-Src kinases (Table 1). All of
the analogues were better inhibitors of the engineered v-
Src than of wild-type v-Src, confirming our prediction of
the binding orientation of 2 in the kinase active site. Any
derivatization of 2 at the N-4 position destroyed the
inhibitory activity against wild-type v-Src (no detectable
inhibition at the limit of solubility, 300 µM). All 10
analogues demonstrated measurable inhibition of I338G 
v-Src, and several of the compounds had IC50 values in the
low micromolar range. The N-4-(p-tert-butyl)benzoyl ana-
logue (3g) was the most potent inhibitor of I338G v-Src in
the panel (IC50 = 430 nM). This molecule showed no inhi-
bition of wild-type v-Src at 300 µM, suggesting that 3g is at
least a 1000-fold better inhibitor of the mutant v-Src than
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Figure 2
(a) Structure of N-6 cyclopentyloxyadenosine (1). (b) Synthesis of
pyrazolo[3,4-d]pyrimidine inhibitor analogues. Compound 2 was
synthesized according to Hanefeld et al. [32]. (i) Acyl chloride
(RCOCl; 10 equivalents), pyridine, 5°C, 1 h; then warm to 22°C, 11 h;
(ii) LiAlH4 (3.0 equivalents), dry tetrahydrofuran under argon, 0°C,
30 min; then heat to reflux for 30 min.
N
NN
N
HN R
N
NN
N
NH2
N
NN
N
HN R
(ii)
cyclobutyl
cyclopentyl
cyclohexyl
2-furyl
phenyl
p-methylphenyl
p-tert-butylphenyl
4b, 4d, 4e
O
3a
3b
3c
3d
3e
3f
3g
2 3a–3g
Compound
4b
4d
4e
cyclopentyl
2-furyl
phenyl
Compound
N
NN
N
(b)
(a) HN
6
5
1
O
OHOH
7
43
HO
R =
O
R =
(i)
1
2
Current Biology
Figure 3
(a) Chemical structures of quercetin (5) and AMPPNP (6). (b)
Predicted binding orientation of 2 in Src family kinase active sites. The
crystal structures of Hck bound to AMPPNP (red) and Hck bound to
quercetin (blue) were superimposed according to the Hck protein
backbone (white) [25]. The structure of 2 (yellow) was subsequently
docked into the kinase active site by superimposing the pyrazolo[3,4-
d]pyrimidine ring system of 2 onto the adenine ring of AMPPNP. (c)
Predicted close contact between N-4 of 2 and the side chain of
residue 338 in Src family kinases. Molecule 2 has been docked into
the ATP-binding site of the Src family kinase Hck as in (b). The atoms
of the Thr338 side chain and 2 are colored according to their
elemental make-up (green, carbon; blue, nitrogen; red, oxygen; white,
hydrogen) and the Hck backbone is shown in pink. The methyl
hydrogens of the threonine side chain are not shown. Images were
generated using the program InsightII.
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of wild-type v-Src. The size of the derivatization needed to
achieve sub-micromolar potency for the I338G v-Src active
site was rather unexpected. We removed only four carbon
atoms from the ATP-binding site of the protein and added
11 carbon atoms to the parent molecule. This discrepancy
may be due to an imperfection in our binding prediction.
Alternatively, the isoleucine to glycine mutation may
confer greater flexibility on the enzyme active site, allow-
ing the mutant kinase to accept a larger inhibitor analogue
than predicted [24]. To confirm that 3g does inhibit I338G
v-Src at the ATP-binding site, we investigated the kinetics
of inhibition at various ATP concentrations. Lineweaver–
Burk analysis confirmed that 3g does inhibit I338G v-Src
competitively with respect to ATP with an inhibitory con-
stant (Ki) of 380 nM (data not shown).
The 10 inhibitor analogues were then screened against
wild-type Fyn to investigate their potential to cross-react
with this kinase. Wild-type Fyn was chosen as the ‘worst
case’ control of wild-type kinases because both 2 and its
parent molecule, PP1, are highly potent (low nanomolar)
inhibitors of Fyn [19]. Many of the inhibitor analogues
were not highly selective for the target kinase (Table 1).
The N-acyl analogues with saturated ring systems (3a–3c)
effectively inhibited wild-type Fyn. The N-methylene
compounds (4b–4e) were sufficiently inactive against wild-
type Fyn but showed only poor to moderate inhibition of
I338G v-Src. Importantly, 3g, the most potent inhibitor of
the mutant v-Src, inhibited wild-type Fyn very weakly
(IC50 = 300 µM). Thus, 3g inhibits the engineered v-Src
over 700 times more effectively than it inhibits wild-type
Fyn, which is likely to be the wild-type cellular kinase that
is the most capable of binding the molecule. We also
tested whether other non-Src family kinases were fortu-
itously inhibited by 3g in vitro. Inhibition of the
serine/threonine kinases protein kinase C δ (PKCδ) and
protein kinase A was not detected at inhibitor concentra-
tions up to 300 µM. Likewise, 3g exhibited only weak
inhibition (IC50 > 300 µM) of Abl. The 3g compound
therefore satisfied all of our initial design requirements for
potent selective inhibition of one engineered kinase. 
Selectivity in whole cells
To demonstrate further that 3g does not inhibit wild-type
tyrosine kinases, we investigated the effects of 3g treat-
ment on the phosphorylation cascade triggered by activa-
tion of the B-cell receptor. Src family (Fyn, Lyn, Lck, Blk)
and non-Src family (Btk, Syk) tyrosine kinases are known
to be activated upon cross-linking of the B-cell receptor
[34]. Because of the amplifying nature of the B-cell recep-
tor signaling cascade, inhibition of any of the downstream
kinases would dramatically alter the distribution and
intensity of post-activation cellular phosphotyrosine [35].
Because 3g was designed to be sterically incompatible
with the active sites of wild-type kinases, it should not
disrupt tyrosine-phosphorylation-dependent signaling in
wild-type B cells. Figure 4 shows that treatment of murine
B cells that had had their antigen receptor cross-linked
with 100 µM 3g had no effect on the phosphotyrosine
pattern of B-cell stimulation (compare lane 3 to lane 2).
The signal intensities of all the major bands were
unchanged and only slight depletion of some minor bands
is detectable, confirming that 3g does not appreciably
inhibit the panel of tyrosine kinases that are activated by
cross-linking the B-cell receptor. Treatment of B cells
with 100 µM 2, however, caused a significant reduction in
tyrosine phosphorylation (Figure 4, lane 4) that is consis-
tent with the ability of 2 to potently inhibit wild-type Src
family kinases [19]. 
Selective inhibition of I338G v-Src in NIH3T3 cells
In order to use our selective inhibitor to study a Src-medi-
ated pathway, we delivered genes encoding either wild-
type or I338G v-Src into NIH3T3 fibroblasts via retrovirus
infection [36]. These cells acquired a transformed pheno-
type that was dependent on v-Src expression. We sought
to show that 3g could selectively inhibit the Src-depen-
dent signal-transduction pathway of I338G v-Src trans-
formed cells but not affect cells transformed with
wild-type v-Src. Cells infected with wild-type v-Src
showed no loss of tyrosine phosphorylation when treated
with 100 µM 3g compared to control treatment with
dimethyl sulfoxide (DMSO; Figure 5), demonstrating that
3g does not inhibit wild-type v-Src or any of the other
tyrosine kinases that are activated by v-Src-mediated
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Table 1
In vitro IC50 values of wild-type and engineered v-Src and Fyn
peptide phosphorylation by pyrazolo[3,4-d]pyrimidine
analogues.
IC50 (µM)
R = Compound v-Src I338G v-Src Fyn T339G Fyn
3a > 300 12 6.5 5
3b > 300 19 80 9
4b > 300 75 > 300 100
3c > 300 20 50 5
3d > 300 150 15 19
4d > 300 250 > 300 26
3e > 300 10 300 11
4e > 300 85 > 300 63
3f > 300 10 300 6
3g > 300 0.43 300 0.83
O
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O
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H R
cellular transformation. When cells infected with I338G 
v-Src were treated with 100 µM 3g, there was a dramatic
decrease in the tyrosine phosphorylation of the putative 
v-Src substrate, p36, as well as a moderate overall decrease
in the cellular level of phosphotyrosine (Figure 5,
lanes 4,5). It has been shown previously that treatment of
v-Src-transformed cells with general tyrosine kinase
inhibitors causes a reduction in the tyrosine phosphoryla-
tion of a 36 kDa protein [31]. It is thought that p36 is
associated with a specific phosphotyrosine phosphatase,
possibly explaining its rapid dephosphorylation in
inhibitor-treated cells [37]. The IC50 of 3g for the p36
phosphotyrosine signal in cells expressing I338G v-Src
was ~50 µM, roughly 100 times the in vitro value (data not
shown). This is presumably because the inhibitor must
compete for the kinase active site with millimolar concen-
trations of ATP in the cellular environment [9].
Selective inhibition of I338G v-Src reverses transformed
cell morphology
The activity of v-Src is required for the transformation of
mammalian cells by the Rous sarcoma virus [38,39].
Treatment of NIH3T3 cells expressing I338G v-Src with
100 µM 3g caused dramatic changes in cell morphology
that are consistent with the reversal of transformation
(Figure 6); the cells appeared flat and did not exhibit the
growth characteristics of transformed cells (that is, the
ability to grow on top of one another). Under identical
conditions, cells infected with wild-type v-Src demon-
strated the typical rounded morphology and overlapping
growth patterns of transformed cells.
To demonstrate further the selective reversal of cell mor-
phology, we used fluorescence microscopy to view 3g-
treated cells after staining the cellular polymerized actin
with fluorescein isothiocyanate–phalloidin (Figure 6).
Non-transformed NIH3T3 cells have long actin fibers that
form across the cells [40]. Cells transformed with v-Src
(both wild-type and I338G forms) appeared rounded with
no discernible pattern of actin fibers. In agreement with
the light microscopy data, inhibitor-treated cells exp-
ressing wild-type v-Src appeared indistinguishable from
262 Current Biology, Vol 8 No 5
Figure 4
Inhibitor analogue 3g does not inhibit tyrosine phosphorylation
triggered by the active B-cell receptor. Murine spleen cells were
incubated with 1.1% DMSO (lanes 1,2), 100 µM 3g in 1.1% DMSO
(lane 3), or 100 µM 2 in 1.1% DMSO (lane 4). B-cell stimulation (lanes
2–4) was initiated by the addition of 10 µg/ml goat anti-mouse IgM.
Cellular proteins were resolved by 10% SDS–PAGE, transferred to
nitrocellulose, and immunoblotted with a monoclonal anti-
phosphotyrosine antibody (4G10).
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Figure 5
Inhibitor 3g blocks p36 phosphorylation in NIH3T3 fibroblasts
transformed with I338G v-Src but not wild-type v-Src. Non-
transformed NIH3T3 cells (lane 1), wild-type v-Src-transformed
NIH3T3 cells (lanes 2,3), and I338G v-Src-transformed NIH3T3 cells
(lanes 4,5) were incubated with 1.1% DMSO (lanes 1,2,4) or 100 µM
3g in 1.1% DMSO (lanes 3,5). After 12 h, the cells were lysed and
protein phosphorylation levels determined as in Figure 4.
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untreated wild-type v-Src cells. The 3g-treated cells
expressing I338G v-Src had defined polymerized actin
strings, however, which strongly resembled the actin for-
mations of non-transformed NIH3T3 fibroblasts. These
3g-treated cells had an exaggerated flattened morphology
and showed peripheral actin staining that was not present
in the non-transformed NIH3T3 cells. These data show
that 3g can induce morphological changes in cells that are
engineered to contain a single amino-acid change in the
kinase of interest. This is the first demonstration that a
small-molecule inhibitor selective for a tyrosine-kinase
oncogene product can revert the morphological changes
associated with cellular transformation. Previous examples
of morphological reversion of transformation by her-
bimycin A (and other benzoquinone ansamycins) have
recently been shown to operate via a mechanism that is
not related to kinase inhibition and consists of targeting of
the oncogenic tyrosine kinase to the proteasome by use of
the heat-shock protein Hsp90 [41–44].
Generalization to other kinases
The advantage of using mutagenesis to provide a unique
molecular difference between the enzyme of interest and
all other enzymes is that the approach should be
extendible across the kinase superfamily, because the
kinase fold is conserved. Almost all known protein
kinases contain a bulky side chain at the position corre-
sponding to residue 338 of v-Src. A space-creating muta-
tion at this position should therefore render any kinase
susceptible to selective inhibition. To test this, we mea-
sured the inhibition of T339G mutant Fyn by the ana-
logues (Table 1). The structure–activity relationships of
the analogues for I338G v-Src and T339G Fyn were
found to be strikingly similar. The 3g compound was the
most potent inhibitor analogue against T339G Fyn, as it
was for I338G v-Src, exhibiting an IC50 of 830 nM. This
corresponds to greater than 300-fold selectivity for
T339G Fyn over wild-type Fyn. The implication from
these data is that multiple tyrosine kinases can be system-
atically engineered to accept one inhibitor analogue pref-
erentially without the need to screen large libraries of
putative inhibitors.
Conclusions
In this report, we describe a novel approach to selective
protein kinase inhibition through the complementary
engineering of kinases sensitive to specific chemicals and
rationally designed inhibitors. We demonstrate that high
selectivity for the target kinase can be achieved in whole
cells, and that active-site inhibition of an oncogenic tyrosine
kinase can be sufficient for the disruption of a transformed
cell morphology. Because the approach is easily general-
ized, it should have far-reaching applications in deconvolut-
ing signal-transduction pathways, as well as in the validation
of kinases as targets for drug design. The pace of effective
drug discovery is limited by the identification and
validation of important drug targets. This is not a trivial
problem in a milieu of homologous proteins that may
potentially number 2000. The use of chemical-sensitive
mutants of protein kinases expands the ability to probe the
cellular and physiological effects of pharmacological kinase
inhibition. As transfected cell lines and even ‘knock-in’
mice expressing a mutant protein of interest can now be
generated rapidly, our approach should greatly expedite the
process of testing the effects of selective inhibition of a
given kinase in a whole-cell or animal model. As more
inhibitor-bound protein kinase crystal structures become
available, our strategy will allow for the systematic
investigation of the effects of time-dependent and 
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Figure 6
Fibroblasts transformed with I338G v-Src acquire a flattened
morphology and regain actin stress fibers when they are incubated
with 3g. (a,b) Non-transformed, (c,d,g,h) wild-type v-Src-transformed,
and (e,f,i,j) I338G v-Src-transformed NIH3T3 fibroblasts were treated
with either 1.1% DMSO (a–c,e,g,i) or 100 µM 3g in 1.1% DMSO
(d,f,h,j). After 48 h, cells were photographed (a,c–f), stained with
FITC–phalloidin, and visualized by fluorescence microscopy (b,g–j).
(c)
(a)
(d)
(f)(e)
100 µM 3gControl
Current Biology
v-
S
rc
(b)
(g)
(i) (j)
(h)
v-
S
rc
v-
S
rc
v-
S
rc
dose-dependent inhibition of any given kinase in the scope
of an entire signal transduction cascade.
Materials and methods
Chemical synthesis
All starting materials and synthetic reagents were purchased from
Aldrich unless otherwise noted. All compounds were characterized by
1H NMR and high resolution mass spectrometry. 4-amino-1-tert-butyl-
3-phenylpyrazolo [3,4-d] pyrimidine (2) was synthesized according to
Hanefeld et al. [32].
General procedure for N-4 acylation of 2 (3a–3g): To a solution of 2
(~100 mg) dissolved in 2 ml pyridine was added 10 equivalents of the
desired acyl chloride at 0°C. The reaction mixture was allowed to warm
to room temperature and stirred for 12 h. The reaction was quenched
by the addition of 25 ml water. The resulting mixture was extracted with
Et2O and the combined Et2O extracts were washed with 1 N HCl and
5% NaHCO3. The Et2O layer was dried over MgSO4 and evaporated.
The residue was purified by flash chromatography on 25 g silica gel by
elution with 1:1 Et2O : hexanes to yield pure 3a–3g.
4-cyclobutylamido-1-tert-butyl-3-phenylpyrazolo[3,4-d]pyrimidine
(3a): Yield 0.0116 g (16%), white powder; HRMS (EI) molecular ion
calculated for C20H23N5O 349.19049, found 349.18762; 1H NMR
(300 MHz, CDCl3, ppm) δ 1.86 (9H, s), 1.89–2.27 (6H, m), 3.58 (1H,
m), 7.26–7.67 (5H, m), 8.69 (1H, s).
4-cyclopentylamido-1-tert-butyl-3-phenylpyrazolo[3,4-d]pyrimidine
(3b): Yield 0.0456 g (68%), white powder; HRMS (EI) molecular ion
calculated for C21H25N5O 363.20615, found 363.20398; 1H NMR
(270 MHz, CDCl3, ppm) δ 1.41–1.91 (8H, m), 1.87 (9H, s), 2.97 (1H,
m), 7.51–7.67 (5H, m), 8.70 (1H, s).
4-cyclohexylamido-1-tert-butyl-3-phenylpyrazolo[3,4-d]pyrimidine
(3c): Yield 0.0575 g (84%), white powder; 1H NMR (270 MHz, CDCl3,
ppm) δ 1.21–1.93 (10H, m), 1.86 (9H, s), 2.43 (1H, m), 7.51–7.67
(5H, m), 8.70 (1H, s).
4-2′-furylamido-1-tert-butyl-3-phenylpyrazolo[3,4-d]pyrimidine (3d):
Yield 0.0342 g (60%), white powder; HRMS (EI) molecular ion calcu-
lated for C20H19N5O2 361.15407, found 361.15254; 1H NMR
(270 MHz, CDCl3, ppm) δ 1.87 (9H, s), 6.52 (1H, d), 7.23 (1H, d),
7.43–7.53 (5H, m), 7.95 (1H, s), 8.59 (1H, s).
4-benzamido-1-tert-butyl-3-phenylpyrazolo[3,4-d]pyrimidine (3e):
Yield 0.1309 g (56%), white powder; HRMS (EI) molecular ion calcu-
lated for C22H21N5O 371.17933, found 371.17324; 1H NMR
(270 MHz, CDCl3, ppm) δ 1.41–1.91 (8H, m), 7.22–8.11 (10H, m),
8.48 (1H, s).
4-(p-methyl)benzamido-1-tert-butyl-3-phenylpyrazolo[3,4-d]pyrimidine
(3f): Yield 0.0751 g (33%), white powder; HRMS (EI) molecular ion
calculated for C23H23N5O 385.19499, found 385.18751; 1H NMR
(270 MHz, CDCl3, ppm) δ 1.88 (9H, s), 2.42 (3H, s), 7.19 (2H, d),
7.41–8.11 (7H, m), 8.49 (1H, s).
4-(p-tert-butyl)benzamido-1-tert-butyl-3-phenylpyrazolo[3,4-d]pyrimi-
dine (3g): Yield 0.1050 g (42%), white powder; HRMS (EI) molecular
ion calculated for C26H29N5O 427.23747, found 427.23474; 1H NMR
(270 MHz, CDCl3, ppm) δ 1.35 (9H, s), 1.88 (9H, s), 7.38–7.99 (9H,
m), 8.50 (1H, s).
General procedure for the reduction of N-4 acyl compounds to N-4
methylene compounds (4b, 4d, 4e): A round bottom flask was
charged with ~30 mg LiAlH4. The flask was equipped with a pressure
equalizing dropping funnel and flushed with dry argon. The LiAlH4 was
suspended in 3 ml THF over an ice bath. Approximately 100 mg of the
corresponding N-4 acyl 2 analogue was dissolved in 5 ml THF and
added dropwise to the suspension of LiAlH4. The reaction mixture was
stirred for 30 min on the ice bath and subsequently heated to reflux for
30 min. The reaction was quenched by the sequential, dropwise addi-
tions of 1 ml EtOAc, 1 ml water, and 1 ml 6 N NaOH. After stirring for
5 min, the reaction mixture was filtered through a celite pad, diluted
with water and extracted with Et2O. The Et2O extracts were combined,
dried over MgSO4, and evaporated. The residue was purified by flash
chromatography on 10 g of silica gel by elution with 4:1
hexanes : EtOAc.
4-cyclopentylmethylamino-1-tert-butyl-3-phenylpyrazolo[3,4-d]pyrimi-
dine (4b): Yield 0.0649 g (75%), clear oil; HRMS (EI) molecular ion
calculated for C21H27N5 349.22691, found 349.22420; 1H NMR
(270 MHz, CDCl3, ppm) δ 1.16–2.14 (9H, m), 1.84 (9H, s), 3.54 (2H,
d), 5.51 (1H, s), 7.46–7.67 (5H, m), 8.43 (1H, s).
4-2′-furylmethylamino-1-tert-butyl-3-phenylpyrazolo[3,4-d]pyrimidine
(4d): Yield 0.0620 g (66%), beige powder; HRMS (EI) molecular ion
calculated for C20H21N5O 347.17483, found 347.17330; 1H NMR
(270 MHz, CDCl3, ppm) δ 1.83 (9H, s), 4.75 (2H, d), 5.64 (1H, s),
6.25 (2H, d), 7.34–7.63 (6H, m), 8.45 (1H, s).
4-benzylamino-1-tert-butyl-3-phenylpyrazolo[3,4-d]pyrimidine (4e):
Yield 0.0520 g (54%), white powder; HRMS (EI) molecular ion calcu-
lated for C22H23N5 357.19559, found 357.19303; 1H NMR (270 MHz,
CDCl3, ppm) δ 1.82 (9H, s), 4.76 (2H, d), 5.63 (1H, s), 7.28–7.63
(10H, m), 8.44 (1H, s).
Protein expression and purification
Site-directed mutagenesis and cloning of the genes for the glutathione-
S-transferase fusion proteins of wild-type v-Src SH1 domain, I338G v-
Src SH1, wild-type Fyn, T339G Fyn, and wild-type Abl into the
pGEX-KT plasmid was carried out as described [23]. These kinases
were expressed in DH5α Escherichia coli and purified on immobilized
glutathione beads (Sigma). PKA was purchased (Pierce) and used
without further purification. PKCδ was expressed as the 6-His con-
struct using the Bac-to-Bac expression system (pFastBac B vector).
PKCδ was purified using a QIAexpress Ni–NTA agarose column.
In vitro kinase inhibition assay
IC50 values for putative kinase inhibitors were determined by measuring
the counts per minute (cpm) of 32P transferred to an optimized peptide
substrate for Src family kinases (IYGEFKKK, in single-letter amino-acid
code). Various concentrations of inhibitor were incubated with 50 mM
Tris (pH 8.0), 10 mM MgCl2, 1.6 mM glutathione, 1 mg/ml BSA,
133 µM IYGEFKKK, 3.3% DMSO, 0.05 µM kinase and 11 nM (2 µCi)
[γ-32P]ATP (6000 Ci/mmol, NEN) in a total volume of 30 µl for 30 min.
Reaction mixtures (25 µl) were spotted onto a phosphocellulose disk,
immersed in 10% HOAc, and washed with 0.5% H3PO4. The transfer
of 32P was measured by standard scintillation counting. The IC50 was
defined to be the concentration of inhibitor at which the cpm was 50%
of the control disk. When the IC50 fell between two measured concen-
trations it was calculated based on the assumption of an inversely pro-
portional relationship between inhibitor concentration and cpm
between the two data points. Because the solubility limit of the inhibitor
analogues in aqueous solutions is ~300 µM, IC50 values of ≥250 µM
are approximate as full titrations to the upper limit of inhibition could not
be tested. IC50 values for non-Src family kinases were measured equiv-
alently with the following exceptions. Kemtide (Pierce, 133 µg/ml) was
used as the substrate for PKA. An optimized Abl substrate (EAIYAAP-
FAKKK, 133 µg/ml) was used for Abl assays. PKCδ assays were per-
formed in the presence of 17 ng/ml diacyl glycerol (Sigma) and
17 ng/ml phosphatidyl serine (Sigma) with 170 ng/ml histone (Sigma)
as the kinase substrate.
Murine B-cell assay
Splenic lymphocytes were isolated from 6–20 week old Balb/c or
C57/B6 mice. The cells were washed out of the spleen into RPMI
media containing 1 µg/ml DNase I and the red-blood cells were lysed
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in 17 mM Tris-ammonium chloride, pH 7.2. Approximately 4 × 106 cells
were incubated at 37°C for 30 min with 100 µM of 3g or 2 in 1.1%
DMSO. B-cell stimulation was initiated by the addition of 2 µg of goat
anti-mouse IgM (Jackson Immuno Research, 115-005-075) and subse-
quent incubation for 5 min at 37°C. The cells were isolated by centrifu-
gation (13,000 rpm, 2 min) and lysed (lysis buffer: 1% Triton X-100,
50 mM Tris pH 7.4, 2 mM EDTA, 150 mM NaCl, 100 µM PMSF, 2 mM
sodium orthovanadate, 10 µg/ml leupeptin, 10 µg/ml apoprotin). The
cellular debris was then pelleted at 13,000 rpm for 15 min. Cellular
proteins were separated by 10% polyacrylamide gel electrophoresis
and transferred to a nitrocellulose membrane by western blotting.
Phosphotyrosine-containing proteins were visualized by immunoblot-
ting with anti-phosphotyrosine antibody (Upstate Biotechnology).
Retroviral infection of NIH3T3 fibroblasts
Genes encoding wild-type and I338G v-Src were transfected into a
packaging cell line and NIH3T3 fibroblasts were retrovirally infected
using the pBabe retroviral vector and a puromycin (2.5 µg/ml) selec-
table marker as described [36] (K.S., Y.L., K.M.S., unpublished obser-
vations). Cells transformed with wild-type and I338G v-Src were
cultured in DMEM/10% BCS containing 2.5 µg/ml puromycin.
Inhibition of v-Src in NIH3T3 fibroblasts
Non-transformed NIH3T3 cells and NIH3T3 cells transformed with
wild-type v-Src or I338G v-Src were incubated at 37°C with 1.1%
DMSO or 100 µM 3g in 1.1% DMSO. After 12 h, the cells were
washed with PBS and lysed (lysis buffer: 1% Triton X-100, 50 mM Tris
pH 7.4, 2 mM EDTA, 150 mM NaCl, 100 µM phenylmethylsulphonyl
fluoride, 2 mM sodium orthovanadate, 10 µg/ml leupeptin, 10 µg/ml
apoprotin). The lysate was clarified by centrifugation at 13,000 rpm for
15 min. Lysate protein concentrations were normalized and equal
volumes of the lysate were resolved by electrophoresis and analyzed
for phosphotyrosine content as described above.
Microscopy
NIH3T3 fibroblasts that were non-transformed or transformed with
wild-type or I338G were grown in DMEM/10% BCS on slides treated
for tissue culture. Cells expressing v-Src were treated with either 1.1%
DMSO or 100 µM 3g in 1.1% DMSO. After 48 h cells were pho-
tographed at 400× magnification through a Nikon TMS light micro-
scope. Immediately following light microscopy, the cells were fixed for
20 min in 3.7% formaldehyde/PBS and permeabilized for 60 sec in
0.2% Triton X-100/PBS. Permeabilized cells were incubated with
200 ng/ml FITC–phalloidin/PBS for 20 min. Slides were rinsed with
PBS and polymerized actin was visualized by fluorescence microscopy
at 600× magnification on a Zeiss fluorescence microscope.
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